Long-Acting PrEP in Europe’s Fight Against HIV
The HIV landscape in Europe paints a picture of progress interwoven with persistent challenges. In 2022, the WHO European region ...
The HIV landscape in Europe paints a picture of progress interwoven with persistent challenges. In 2022, the WHO European region ...
MILAN — Ocrelizumab (Ocrevus) effectively prevents relapse in older patients with multiple sclerosis, researchers have shown for the first time, ...
HAMBURG, Germany — Once weekly glucagon-like peptide 1 receptor agonist (GLP-1 RA) semaglutide (Ozempic, Novo Nordisk) significantly improved A1c level ...
TOPLINE: Vegetarian diets may reduce the risk for gastric and colorectal cancers, according to the results of a meta-analysis. METHODOLOGY: ...
Antidiabetic drug tirzepatide (Mounjaro) shows superiority over semaglutide (Ozempic, Wegovy, and Rybelsus) in controlling blood glucose as well as in ...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization of lebrikizumab ...
Minimizing atrial pacing does not alter the risk of atrial fibrillation (AF) associated with sinus node dysfunction (SND), suggest results ...
The European Society of Cardiology has released new guidelines for cardiomyopathies, their first major comprehensive international guidelines to address diagnosis ...
Some clinicians say it's "confusing" and "ridiculous" to change the name and diagnostic criteria of an established liver disease, while ...
Use of GLP-1 agonists, such as semaglutide, surged among US adults with type 2 diabetes in recent years, through March ...
© Pharma News Hubb All rights reserved.
Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.
© 2022 Pharma News Hubb All rights reserved.